Article info
PDFEditorial commentary
Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis
- Correspondence to Dr Hiroki Masuda, Neurology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan; hiroki_masuda{at}chiba-u.jp
Citation
Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis
Publication history
- Received June 28, 2021
- Accepted July 4, 2021
- First published October 19, 2021.
Online issue publication
November 16, 2021
Article Versions
- Previous version (19 October 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.